Company
RyboDyn
RyboDyn is pioneering immunotherapy development by unlocking the dark proteome with our proprietary RyboCypher™ technology.
Also known as Rybodyn, Inc.
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Legal name
- Rybodyn, Inc.
Claim, correct or request removal
Record updated 28 September 2026
About
RyboDyn is a pioneering immunotherapy developer on a mission to transform the way we approach human health. By unlocking the secrets of the dark proteome, we’re redefining patient care with breakthrough therapies that target previously hidden markers of disease.
Funding snapshot
- Total raised
- $5.3MSum of rounds, as of 2026-09-17Source (opens in a new tab)
- Latest round
- Grant, $1.3M2026-07-09
Funding rounds
- Grant
- $1.3M2026-07-09, Company stated
- Seed
- 2026-03-24
- Pre seed
- $4M2025-01-09, Company stated
Products
- Other
- RyboCypher™
Loading relationship preview